Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2009 Results
Date:11/2/2009

ROCKVILLE, Md., Nov. 2 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2009.

Vanda reported a net loss of $7.7 million for the third quarter of 2009, compared to $12.4 million for the second quarter of 2009 and $10.9 million for the third quarter of 2008. Total expenses for the third quarter of 2009 were $7.7 million, compared to $12.4 million for the second quarter of 2009 and $11.2 million for the third quarter of 2008. Research and development (R&D) expenses for the third quarter of 2009 were $2.1 million, compared to $7.2 million for the second quarter of 2009 and $3.8 million for the third quarter of 2008. The decrease in R&D expenses in the third quarter of 2009 relative to the second quarter of 2009 is primarily due to the regulatory consulting fees accrued in the second quarter as a result of the approval of Fanapt(TM) (iloperidone) by the U.S. Food and Drug Administration (FDA). The decrease in R&D expenses in the third quarter of 2009 relative to the third quarter of 2008 is primarily due to the completion of the Phase III clinical trial of tasimelteon in chronic primary insomnia in 2008.

As of September 30, 2009, Vanda's cash, cash equivalents, and marketable securities totaled approximately $20.7 million. As of September 30, 2009, a total of approximately 27.2 million shares of Vanda common stock were outstanding. Net loss per common share for the third quarter of 2009 was $0.28, compared to $0.46 for the second quarter of 2009 and $0.41 for the third quarter of 2008.

OPERATIONAL HIGHLIGHTS

On Octobe
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
2. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
3. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
4. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
5. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
6. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
7. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
8. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
9. Vanda Pharmaceuticals VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
10. Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
11. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (HealthDay News) -- The United States is now ... nations of West Africa land at one of ... with the virus. In a statement released ... 94 percent of air passengers from Guinea, Liberia ... these five airports -- New York City,s Kennedy ...
(Date:10/22/2014)... D.C. (PRWEB) October 22, 2014 With the ... a national survey by the American Institutes for Research (AIR) ... know how to use health insurance, but 42 percent say ... a plan’s details before signing up for coverage. , The ... with only 20 percent able to calculate correctly how much ...
(Date:10/22/2014)... October 22, 2014 Losing Weight Your Body’s ... is staring you in the face, it certainly can be ... do your body an extra favor by doing it the ... crash diets. Instead, listen to your body, exercise regularly, and ... is essential to losing weight; you need to exercise more ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... ... Washington Hospital Center unveils new state-of-the-art ... include all negative pressure isolation rooms: surfaces made of ... uniquely designed work spaces. The features are designed ...
... N.J., Jan. 8 Medco Health,Solutions, Inc. (NYSE: ... today,reiterated the company,s positive outlook for 2008 at the ... company reiterated its guidance for 2008 GAAP diluted earnings ... that,existed when Medco became a publicly traded company, Medco ...
... carriers , , TUESDAY, Jan. 8 (HealthDay News) -- Not ... show the same risk for developing breast cancer. , ... risk among families carrying the mutations, indicating that the ... factors. , "Risk among carriers varies considerably, and, if ...
... a stage, then proteins would rank among the lead ... These large biological molecules hold many starring roles, and ... genes. They are production powerhouses, regulating the basic processes ... that produce or use energy. Others regulate genes. , ...
... Will Work to Prevent Sudden Cardiac Arrest, ... 8 The Sudden Cardiac Arrest,Association (SCAA) announced ... Minnesota affiliates as it builds a network,of local ... preventing sudden,cardiac arrest (SCA)., The Minnesota SCAA ...
... Groups Will Work to Prevent Sudden Cardiac Arrest Through ... Chapters/Affiliates by This Spring, WASHINGTON, Jan. 8 ... has launched its first 13 local,chapter and affiliate organizations, ... carry out its mission of preventing sudden cardiac,arrest., ...
Cached Medicine News:Health News:Hospital Launches Landmark Project in Emergency Medicine 2Health News:Medco CEO Reiterates Guidance, Positive Outlook for 2008 2Health News:BRCA Mutations Don't Raise Breast Cancer Risk Equally 2Health News:BRCA Mutations Don't Raise Breast Cancer Risk Equally 3Health News:Protein power: Researchers trigger insulin production in diabetic mice 2Health News:Protein power: Researchers trigger insulin production in diabetic mice 3Health News:Sudden Cardiac Arrest Association Launches Two Minnesota Affiliates 2Health News:Sudden Cardiac Arrest Association Launches Two Minnesota Affiliates 3Health News:Sudden Cardiac Arrest Association Launches Its First Thirteen Local Chapters/Affiliates 2Health News:Sudden Cardiac Arrest Association Launches Its First Thirteen Local Chapters/Affiliates 3
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
(Date:10/22/2014)... 21, 2014   BioNano Genomics , the ... research centers to purchase an Irys™ System . ... Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) and ... obtaining a comprehensive view of a genome was ... does not deliver the scalability or reliability to ...
(Date:10/22/2014)... CAMBRIDGE, Mass. , Oct. 22, 2014 ... Cambridge, MA is revolutionizing spinal cord ... technique has been shown to outperform in tissue regrowth ... with the scaffold.  Made from an FDA approved polymer, ... dioxide; making it harmless to the human body. NVIV ...
Breaking Medicine Technology:AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... ClinicROCHESTER, Minn., March 23 Here are highlights ... Clinic,s research magazine. You may cite and link ... Reprinting is allowed with proper attribution. Please include ... permit: Visit http://discoverysedge.mayo.edu for subscription information.Parkinsonism: ...
... PLCO trial was started, we have awaited the results of ... report of the results of this study -- and those ... the New England Journal of Medicine have told us two ... evidence about the possibility of a prostate cancer-specific survival benefit ...
Cached Medicine Technology:Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 3
Ideal for chest procedures....
Male Compression Vests...
Female Compression VEST w/sleeves...
Male Support Brief...
Medicine Products: